Charting A New Course

for cell therapy to reach more patients

Catamaran is engineering NK cell therapies to provide transformative off-the-shelf treatments for solid tumors and other cancers.

Photo of NK cells with electronic circuitry

A highly differentiated approach for allogeneic cell therapy

Catamaran harnesses the natural cancer-fighting properties of NK cells, the power of synthetic biology and innovative non-viral cell engineering to create novel CAR-NK cell therapies for the treatment of more patients and more cancer types, especially solid tumors. Learn more

Infographic of catamaran platform

Our TAILWIND® platform is a proprietary and integrated suite of technologies to engineer, expand and process NK cells into safe and highly potent allogeneic CAR-NK cell therapy products.
Learn More

Innovation in NK cell therapy is the guiding focus of our team

At Catamaran, our guiding focus is to drive innovation in cell therapy to treat more patients. Our scientific founders, Branden Moriarity, PhD and Dr. Catherine Bollard, MD, are pioneers in NK cell biology, engineering, manufacturing and clinical application. Our internal Catamaran team combines its deep expertise in cell therapy with a passion for developing paradigm-shifting therapies. See more about our team

Compass pointing North

Follow your True North – Join our crew

If you are passionate about developing more effective treatments for cancer patients, you believe in the promise of cell therapy, and you want to put your career on a high-growth course, come and set sail with us!

Latest News

  • || Catamaran Bio Announces Preclinical Data from Allogeneic CAR-NK Cell Therapy Pipeline for Solid Tumors to be Presented at the American Association for Cancer Research (AACR) Annual Meeting 2023

    Full Release

  • || Catamaran Bio selects OmniaBio as partner to develop and manufacture allogeneic CAR-NK cell therapies

    Full Release

  • || MaxCyte Signs Strategic Platform License with Catamaran Bio to Support its CAR-NK Cell Therapy Programs

    Full Release

Our focus is on reaching more cancer patients with safe and highly potent cell therapies.